NCT03527615

Brief Summary

Initiative to improve direct anticoagulant utilization involving programmatic review by clinical pharmacists in collaboration with multidisciplinary team.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
4,000

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started Jan 2017

Typical duration for all trials

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

January 1, 2017

Completed
1.3 years until next milestone

First Submitted

Initial submission to the registry

April 16, 2018

Completed
1 month until next milestone

First Posted

Study publicly available on registry

May 17, 2018

Completed
1.6 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

January 1, 2020

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

January 1, 2020

Completed
Last Updated

May 17, 2018

Status Verified

April 1, 2018

Enrollment Period

3 years

First QC Date

April 16, 2018

Last Update Submit

May 16, 2018

Conditions

Safety IssuesAnticoagulant Toxicity

Outcome Measures

Primary Outcomes (1)

  • Percent of clinical pharmacist consultations accepted by attending physician.

    Calculated by dividing the number of clinical pharmacist consultations accepted, by the number of clinical pharmacist consultations given, during the period. Data for consultation counts will be obtained from patient electronic medical record.

    At forty-eight months

Secondary Outcomes (1)

  • Percent of clinical pharmacist consultations accepted by attending physician.

    At six months

Interventions

Clinical Pharmacist Medication ReviewOTHER

Programmatic review of physician orders for direct anticoagulants by clinical pharmacists.

Eligibility Criteria

Sexall
Healthy VolunteersNo
Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)
Sampling MethodNon-Probability Sample
Study Population

Patients hospitalized in Hadassah Medical Center with a physician's order for direct oral anticoagulants.

You may qualify if:

  • Patients hospitalized in Hadassah Medical Center with a physician's order for direct oral anticoagulants (apixaban, rivaroxaban, or dabigatran).

You may not qualify if:

  • Patients hospitalized in departments without computerized physician order entry.

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Hadassah Medical Organization, Jerusalem, Israel

Jerusalem, Israel

RECRUITING

Related Publications (1)

  • Perlman A, Horwitz E, Hirsh-Raccah B, Aldouby-Bier G, Fisher Negev T, Hochberg-Klein S, Kalish Y, Muszkat M. Clinical pharmacist led hospital-wide direct oral anticoagulant stewardship program. Isr J Health Policy Res. 2019 Feb 1;8(1):19. doi: 10.1186/s13584-019-0285-9.

    PMID: 30709417DERIVED

Study Officials

  • Mordechai Muszkat, MD

    Hadassah University Medical Center

    PRINCIPAL INVESTIGATOR

Central Study Contacts

Amichai Perlman, Pharmd

CONTACT

972505172768amichaip@hadassah.org.il

Study Design

Study Type
observational
Observational Model
COHORT
Time Perspective
RETROSPECTIVE
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

April 16, 2018

First Posted

May 17, 2018

Study Start

January 1, 2017

Primary Completion

January 1, 2020

Study Completion

January 1, 2020

Last Updated

May 17, 2018

Record last verified: 2018-04

Data Sharing

IPD Sharing
Will not share

Locations

IL(1)